Chong Kun Dang Pharmaceutical EBIT

As of the most recent data (June 2026), 185750.KS shows a EBIT of $78B. That compares with $180B in the prior-year period — down 57.0% year over year. That is below the sector sector average of $2.6T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 185750.KS's EBIT is now $78B (was $180B) — a 57.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Chong Kun Dang Pharmaceutical is outperforming or lagging.

The its sector sector average EBIT is about $2.6T. Chong Kun Dang Pharmaceutical is at $78B, which is lower that average. That is roughly 96.9% below the sector mean. Use the comparison chart on this page to see how 185750.KS stacks up against individual peers as well.

Tracking 185750.KS's ebit over time shows whether Chong Kun Dang Pharmaceutical is scaling, shrinking, or reshaping that part of the business. The current reading is $78B That compares with $180B in the prior-year period — down 57.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Chong Kun Dang Pharmaceutical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $78B) with ownership activity and broader fundamentals.